GlassScriptPhysician profile
Adam M Goldstein
NPI 1083685382
$1,184.46
in general payments reported to CMS, 2019-2025
12 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $92.90 · 2021: $217 · 2022: $28.00 · 2024: $259 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502 · Education: $8.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.11 |
| Education | $8.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $255.75 | 2019-2024 | |
| Novo Nordisk INC | $245.97 | 2025 | Wegovy, Ozempic |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Amgen INC. | $150.08 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $124.98 | 2024 | |
| Intuitive Surgical, INC. | $94.51 | 2019 | |
| Fresenius USA Marketing, INC. | $30.41 | 2019-2020 | |
| Akebia Therapeutics INC | $21.39 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.86 | 2019 | |
| Preventice Services, LLC | $17.15 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Travere Therapeutics, INC. | $8.80 | 2024-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.